<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>건강과 대안 &#187; extracorporeal membrane oxygenation</title>
	<atom:link href="http://www.chsc.or.kr/tag/extracorporeal%20membrane%20oxygenation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.chsc.or.kr</link>
	<description>연구공동체</description>
	<lastBuildDate>Mon, 13 Apr 2026 01:34:28 +0000</lastBuildDate>
	<language>ko-KR</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.2</generator>
		<item>
		<title>[돼지독감] 호주의 2009 겨울 신종플루 분석(NEJM)</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=1447</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=1447#comments</comments>
		<pubDate>Thu, 26 Nov 2009 11:10:12 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[ECMO]]></category>
		<category><![CDATA[extracorporeal membrane oxygenation]]></category>
		<category><![CDATA[intensive care units]]></category>
		<category><![CDATA[돼지독감]]></category>
		<category><![CDATA[신종플루]]></category>
		<category><![CDATA[중증환자 관리체계]]></category>
		<category><![CDATA[중환자실]]></category>
		<category><![CDATA[체외막형산소섭취]]></category>
		<category><![CDATA[호주 2009 겨울]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=1447</guid>
		<description><![CDATA[2009 인플루엔자 A(H1N1)v의 1차 파고가 지나간 호주의 2009 겨울(2009년 5월 중순~9월 말)에 대한 분석자료입니다.이 기간 동안 influenza-like illness&#160;증상으로 병원에서 진찰을&#160;받은 사람은 최고조에 달했을 때 병원 래원자 1000명 당&#160;34명~38명이었다고 [...]]]></description>
				<content:encoded><![CDATA[<p><P>2009 인플루엔자 A(H1N1)v의 1차 파고가 지나간 호주의 2009 겨울(2009년 5월 중순~9월 말)에 대한 분석자료입니다.<BR><BR>이 기간 동안 influenza-like illness<SUP>&nbsp;</SUP>증상으로 병원에서 진찰을&nbsp;받은 사람은 최고조에 달했을 때 병원 래원자 1000명 당&nbsp;34명~38명이었다고 합니다. 그 중에서&nbsp; 최고조에 달했을 때 38~65%가 2009 인플루엔자 A(H1N1)v 양성반응이 나왔습니다. 감염자의 90%는 8주까지 초기에 발생했다고 합니다. 학생들의 학교 결석율은 계절성 독감이 최악으로 유행했던 2007년과 비슷했다고 합니다. <BR><BR>입원율은 10만명 당 23명이었으며, 입원환자의 13%는 중환자실(intensive care units)에 입원하였습니다. 5세 이하의 영유아 집단이 가장 높은 입원율을 기록했으며, 5세 이하 남아의 입원율은 10만 명당 67.9명이었으며, 5세 이하 여아의 입원율은 10만명 당 54.1명이었습니다. 참고로 5세 이하의 영우는 2008년 계절성 독감으로 10만명 당 51.1명을 기록했습니다.<BR><BR>평균 입원기간은 3일 이었으며, 19%의 환자가 1주일 이상 입원했습니다. <BR><BR>백만명 당 2.1명의 환자에게 엑크모(extracorporeal membrane<SUP> </SUP>oxygenation ; ECMO ; 체외막형산소섭취)를 시행했는데, 이들 중 2/3가 생존했습니다.<BR><BR>중환자실에 입원한 환자는 10만명 당 3.5명이었으며, 평균연령은 42세였습니다. 20세 이상의 성인 387명이 2009 인플루엔자 A(H1N1)v 감염에 의한 바이러스성 폐렴으로 입원하였는데, 이는 2005년~2008년 바이러스성 폐렴으로 입원한 환자가 매년 평균 57명이었다는 사실과 비교해볼 때 2009 인플루엔자 A(H1N1)v가 호주의 의료체계에 상당한 부담을 안겼음을 알 수 있습니다. </P><br />
<P>결국 호주의 2009 겨울 신종플루의 대응 중에서 가장 중요한 것은 ECMO 장비, 입원 병상, 중환자실(ICU)&nbsp; 입원병상이었다는 교훈을 얻을 수 있습니다. 다시 말해 유럽연합질병관리본부의 위험분석에서 &#8216;위험정보교환&#8217;과 &#8216;중증환자 관리체계&#8217;가 신종플루 피해를 줄이기 위한 가장 핵심적 요소라는 내용이 과학적이며 현실적인 타당한 분석이었다는 것을 확인해줬다고 볼 수 있습니다.<BR><BR></P><br />
<P><BR><BR><STRONG>Published at www.nejm.org November 25, 2009 (10.1056/NEJMp0910445)</STRONG> </P><br />
<P><br />
<DIV align=center><B><FONT face="Arial, Helvetica, sans-serif" size=+2>Australia&#8217;s Winter with the 2009 Pandemic Influenza A (H1N1) Virus</FONT></B><BR></DIV><!-- PLUGH $RESOURCE.EXT_DOI is 10.1056/NEJMp0910445 --><br />
<CENTER><FONT size=+1><I>James F. Bishop, M.D., Mary P. Murnane, B.A., and Rhonda Owen, B.Sc. </I></FONT></CENTER><br />
<P>When the World Health Organization declared a &#8220;public health<SUP> </SUP>emergency of international concern&#8221; on April 25, 2009, after<SUP> </SUP>the emergence in Mexico of pandemic influenza A (H1N1) virus,<SUP> </SUP>Australia activated its well-rehearsed plan for response to<SUP> </SUP>pandemic influenza.<A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#R1"><SUP>1</SUP></A> The Australian Health Management Plan for<SUP> </SUP>Pandemic Influenza is a strategic outline, based on evidence<SUP> </SUP>and international best practices, of actions and interventions<SUP> </SUP>that the health care community should consider taking during<SUP> </SUP>a pandemic. It describes the planning assumptions, the phases<SUP> </SUP>of a response, and the key actions that minimize a pandemic&#8217;s<SUP> </SUP>effects on the population and the health care community. Over<SUP> </SUP>the subsequent 6 weeks, the implementation of border-control<SUP> </SUP>measures — including requirements that travelers entering<SUP> </SUP>Australia declare whether they have symptoms of influenza or<SUP> </SUP>have been in contact with someone with severe respiratory illness<SUP> </SUP>and that contacts of persons with known influenza be traced<SUP> </SUP>— gave the health care community time to learn more about<SUP> </SUP>the natural history of the new influenza strain.<A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#R2"><SUP>2</SUP></A><SUP> </SUP></P><br />
<P>The groups that had been identified worldwide as the most vulnerable<SUP> </SUP>to poor outcomes were pregnant women, indigenous populations,<SUP> </SUP>and persons with gross obesity or serious underlying medical<SUP> </SUP>conditions. Australia pursued a modified version of its national<SUP> </SUP>plan for pandemic influenza, under which such persons and those<SUP> </SUP>with rapidly progressing influenza and respiratory distress<SUP> </SUP>were targeted for early outpatient-based treatment with antiviral<SUP> </SUP>medication and careful follow-up by primary care physicians<SUP> </SUP>and hospitals. Additional public health mitigation measures<SUP> </SUP>included opening the national stockpile of antiviral medication,<SUP> </SUP>providing personal protective equipment to general practitioners,<SUP> </SUP>issuing public messages recommending self-quarantine at home<SUP> </SUP>for persons with influenza-like illness, and launching public-awareness<SUP> </SUP>campaigns aimed at reducing droplet spread of the disease.<SUP> </SUP><br />
<P>This first wave of 2009 pandemic influenza A (H1N1) virus infection<SUP> </SUP>lasted about 18 weeks in Australia, from mid-May to late September<SUP> </SUP>2009 (see <A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#F1">graph</A>).<A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#R3"><SUP>3</SUP></A> Consultations for influenza-like illness<SUP> </SUP>in general practices and emergency departments peaked at 34<SUP> </SUP>and 38 per 1000 consultations, respectively. The percentage<SUP> </SUP>of clinical isolates that tested positive for influenza A peaked<SUP> </SUP>at 38 to 65% in the various states and territories, and the<SUP> </SUP>2009 H1N1 virus accounted for 90% of influenza A isolates by<SUP> </SUP>week 8 (see <A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#F2">maps</A>). Rates of absenteeism from work and school<SUP> </SUP>were similar to those seen in 2007, the year in which Australia<SUP> </SUP>had its worst recent influenza season. The rate of hospitalizations<SUP> </SUP>was 23 per 100,000 population, with indigenous Australians overrepresented<SUP> </SUP>(16%) and about 13% of all patients who were hospitalized being<SUP> </SUP>admitted to intensive care units (ICUs). The highest rate of<SUP> </SUP>hospitalization occurred among children under 5 years of age.<SUP> </SUP>Boys younger than 5 years of age were hospitalized at rate of<SUP> </SUP>67.9 per 100,000 population, and girls in that age group at<SUP> </SUP>a rate of 54.1 per 100,000 population, as compared with 51.1<SUP> </SUP>per 100,000 population in this age group during previous influenza<SUP> </SUP>seasons. The median length of stay was 3 days, with 19% of patients<SUP> </SUP>being hospitalized for more than 7 days.<SUP> </SUP><br />
<P><A name=F1><!-- null --></A><br />
<TABLE cellSpacing=0 cellPadding=0><br />
<TBODY><br />
<TR bgColor=#e8e8d1><br />
<TD><br />
<TABLE cellSpacing=2 cellPadding=2><br />
<TBODY><br />
<TR bgColor=#e8e8d1><br />
<TD vAlign=top align=middle bgColor=#ffffff><A href="http://content.nejm.org/cgi/content/full/NEJMp0910445v1/F1"><IMG height=91 alt="Figure 1" hspace=10 src="http://content.nejm.org/content/vol0/issue2009/images/small/NEJMp0910445f1.gif" width=128 vspace=5 border=2></A><BR><STRONG>View larger version</STRONG> (28K):<BR><NOBR><A href="http://content.nejm.org/cgi/content/full/NEJMp0910445v1/F1">[in this window]</A><BR><A _onmouseover="window.status='View figure in a separate window'; return true" _onclick="startTarget('F1', 590, 514); this.href='/cgi/content-nw/full/NEJMp0910445v1/F1'" href="http://content.nejm.org/cgi/content-nw/full/NEJMp0910445v1/F1" target=F1>[in a new window]</A><BR><A href="http://content.nejm.org/cgi/powerpoint/NEJMp0910445v1/F1"><IMG alt="Get Slide" src="http://content.nejm.org/icons/powerpoint/get_pp_slide_center.gif" vspace=8 border=0></A><BR>&nbsp;</NOBR> </TD><br />
<TD vAlign=top align=left>The Geographic Spread of the 2009 Influenza A (H1N1) Virus in Australia.<br />
<P>Data are from the Australian Influenza Surveillance Reports.<br />
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>&nbsp;<BR><A name=F2><!-- null --></A><br />
<TABLE cellSpacing=0 cellPadding=0><br />
<TBODY><br />
<TR bgColor=#e8e8d1><br />
<TD><br />
<TABLE cellSpacing=2 cellPadding=2><br />
<TBODY><br />
<TR bgColor=#e8e8d1><br />
<TD vAlign=top align=middle bgColor=#ffffff><A href="http://content.nejm.org/cgi/content/full/NEJMp0910445v1/F2"><IMG height=128 alt="Figure 2" hspace=10 src="http://content.nejm.org/content/vol0/issue2009/images/small/NEJMp0910445f2.gif" width=101 vspace=5 border=2></A><BR><STRONG>View larger version</STRONG> (38K):<BR><NOBR><A href="http://content.nejm.org/cgi/content/full/NEJMp0910445v1/F2">[in this window]</A><BR><A _onmouseover="window.status='View figure in a separate window'; return true" _onclick="startTarget('F2', 498, 640); this.href='/cgi/content-nw/full/NEJMp0910445v1/F2'" href="http://content.nejm.org/cgi/content-nw/full/NEJMp0910445v1/F2" target=F2>[in a new window]</A><BR><A href="http://content.nejm.org/cgi/powerpoint/NEJMp0910445v1/F2"><IMG alt="Get Slide" src="http://content.nejm.org/icons/powerpoint/get_pp_slide_center.gif" vspace=8 border=0></A><BR>&nbsp;</NOBR> </TD><br />
<TD vAlign=top align=left>The Frequency of Laboratory-Confirmed 2009 Influenza A (H1N1) Virus Infection in Australia.<br />
<P>Data are from the Australian Influenza Surveillance Reports and are organized according to statistical divisions defined by the Australian Bureau of Statistics; an area under the unifying influence of one or more major towns or cities constitutes a statistical division.<br />
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>&nbsp;<BR>Intensive care specialists identified some patients with confirmed<SUP> </SUP>2009 influenza A (H1N1) virus infection and &#8220;lung-only&#8221; single-organ<SUP> </SUP>failure whose lung function could not be sustained with the<SUP> </SUP>use of ventilators. Among these patients, extracorporeal membrane<SUP> </SUP>oxygenation (ECMO) was used extensively.<A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#R4"><SUP>4</SUP></A> Approximately 2.1<SUP> </SUP>patients per million population were treated with ECMO, and<SUP> </SUP>two thirds of these patients survived.<SUP> </SUP><br />
<P>A distinguishing feature of the epidemic was the number of people<SUP> </SUP>who were hospitalized in ICUs with confirmed cases of pandemic<SUP> </SUP>H1N1 influenza (3.5 per 100,000) and their young age (median,<SUP> </SUP>42 years). According to data from influenza reports and from<SUP> </SUP>the Australian government, a total of 387 adults (over 20 years<SUP> </SUP>of age) were admitted with viral pneumonitis resulting from<SUP> </SUP>influenza A, as compared with a median of only 57 adults per<SUP> </SUP>year admitted with viral pneumonitis from any cause between<SUP> </SUP>2005 and 2008. The peak of the epidemic in Australia lasted<SUP> </SUP>about 3 weeks, and although the Australian health system was<SUP> </SUP>stressed, there was spare capacity of ECMO equipment, hospital<SUP> </SUP>beds, and ICU beds.<SUP> </SUP><br />
<P>Before the 2009 H1N1 virus reached Australia, there were dire<SUP> </SUP>predictions that the country would see many thousands of deaths<SUP> </SUP>from infection with this virus. In reality, 190 deaths associated<SUP> </SUP>with the virus have been confirmed to date, although some additional<SUP> </SUP>cases may not have been documented. A broader measure of all<SUP> </SUP>Australian deaths resulting from influenza or pneumonia currently<SUP> </SUP>indicates that there have been fewer such deaths than in other<SUP> </SUP>influenza or winter seasons.<A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#R3"><SUP>3</SUP></A> However, this year the median<SUP> </SUP>age of the patients who died was 53 years, as compared with<SUP> </SUP>83 years in previous seasons. The lower-than-expected number<SUP> </SUP>of deaths could reflect the success of public health mitigation<SUP> </SUP>measures, the use of early antiviral therapy against a sensitive<SUP> </SUP>virus, and the natural history of this illness, which tends<SUP> </SUP>to be moderate in most people rather than severe.<SUP> </SUP><br />
<P>A national vaccination program was begun in Australia on September<SUP> </SUP>30, 2009, using a monovalent, unadjuvanted 2009 influenza A<SUP> </SUP>(H1N1) vaccine (Panvax, CSL Biotherapies).<A href="http://content.nejm.org/cgi/content/full/NEJMp0910445#R5"><SUP>5</SUP></A> In clinical trials<SUP> </SUP>of this vaccine, Australian participants had higher than expected<SUP> </SUP>levels of protective cross-reactive antibodies, although the<SUP> </SUP>implications of this finding are uncertain. It is possible that<SUP> </SUP>more asymptomatic infections had already occurred. This vaccination<SUP> </SUP>program should provide a higher level of protection for the<SUP> </SUP>Australian population against an anticipated second wave of<SUP> </SUP>infection with the virus.<SUP> </SUP><br />
<P>Key lessons so far from this experience in an unprotected population<SUP> </SUP>suggest that important elements of the response were a national<SUP> </SUP>coordination of efforts and the use and modification of the<SUP> </SUP>national pandemic plan framework, focusing on persons who were<SUP> </SUP>most at risk. The spread of the epidemic occurred earlier in<SUP> </SUP>some geographic locations than in others, which created challenges<SUP> </SUP>(such as implementing the school closure policy) in terms of<SUP> </SUP>maintaining a coordinated national approach to the epidemic.<SUP> </SUP>This challenge was addressed in part by holding regular meetings<SUP> </SUP>of the cross-jurisdictional Australian Health Protection Committee.<SUP> </SUP>Public messages regarding the public health response used the<SUP> </SUP>names of the phases of the pandemic plan, including &#8220;Delay,&#8221;<SUP> </SUP>&#8220;Contain,&#8221; and &#8220;Protect,&#8221; which may have helped the public to<SUP> </SUP>take appropriate personal action and reduce the impact of the<SUP> </SUP>virus on our population.<SUP> </SUP><br />
<P><SUP></SUP><br />
<P><FONT size=-1>Financial and other <A href="http://content.nejm.org/cgi/content/full/NEJMp0910445/DC1">disclosures</A> provided by the authors are<SUP> </SUP>available with the full text of this article at NEJM.org.<SUP> </SUP><br />
<P></FONT><FONT size=-1></FONT><BR><FONT face="arial, helvetica" size=+1><STRONG>Source Information</STRONG></FONT><FONT size=3> </FONT><br />
<P><FONT size=-1>From the Department of Health and Ageing, Canberra, ACT, Australia.<SUP> </SUP><BR><BR>This article (10.1056/NEJMp0910445) was published on November 25, 2009, at NEJM.org. </FONT><br />
<P><FONT face="arial, helvetica" size=+1><STRONG>References</STRONG></FONT><br />
<P><br />
<OL compact><A name=R1><!-- null --></A><br />
<LI value=1>Australian health management plan for pandemic influenza. Canberra: Australian Government Department of Health and Ageing, 2008.<!-- HIGHWIRE ID="0:2009:NEJMp0910445v1:1" -->&nbsp;<!-- /HIGHWIRE --><A name=R2><!-- null --></A><br />
<LI value=2>Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009;360:2616-2625. [Erratum, N Engl J Med 2009;361:102.]<!-- HIGHWIRE ID="0:2009:NEJMp0910445v1:2" -->&nbsp;<A href="http://content.nejm.org/cgi/ijlink?linkType=ABST&#038;journalCode=nejm&#038;resid=360/25/2616"><NOBR>[Free&nbsp;Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE --><A name=R3><!-- null --></A><br />
<LI value=3>Australian Government Department of Health and Ageing. Australian influenza surveillance report no. 21: reporting period 26 September–2 October 2009. (Accessed November 20, 2009, at <A href="http://www.healthemergency.gov.au/">http://www.healthemergency.gov.au</A>.)<!-- HIGHWIRE ID="0:2009:NEJMp0910445v1:3" --><!-- /HIGHWIRE --><A name=R4><!-- null --></A><br />
<LI value=4>The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009;361:1925-1934.<!-- HIGHWIRE ID="0:2009:NEJMp0910445v1:4" -->&nbsp;<A href="http://content.nejm.org/cgi/ijlink?linkType=ABST&#038;journalCode=nejm&#038;resid=361/20/1925"><NOBR>[Free&nbsp;Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE --><A name=R5><!-- null --></A><br />
<LI value=5>Greenberg ME, Lai MH, Hartel GF, et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine — preliminary report. N Engl J Med 2009;361. DOI: 10.1056/NEJMoa0907413.<!-- HIGHWIRE ID="0:2009:NEJMp0910445v1:5" --><!-- /HIGHWIRE --></LI></OL><br />
<P><!-- TEXT --><BR><BR><BR></P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=1447/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
